MICRoMED – Microbial Restoration of intestinal Metabolite balance for type 2 Diabetes 11915 "The microbial population in the gut and the metabolites it produces play an important role in health. Metabolites have a significant signalling role

“肠道微生物组，即居住在人类胃肠道的细菌，病毒和真菌的集合，对健康免疫系统的发育和维持具有深远的影响。从出生开始，微生物组就影响着人类免疫系统对常驻和入侵微生物的反应，这反过来又影响着我们对常见疾病的易感性和长期健康结果。微生物组研究的最新进展突出了健康肠道在预防几种疾病中的重要性，从肠易激综合征到炎症性肠病如克罗恩病和溃疡性结肠炎，抗生素相关腹泻（包括艰难梭菌相关疾病），自闭症，肥胖和2型糖尿病。存在于肠道中的细菌通过制造不仅影响肠道内壁而且在整个身体中具有广泛影响的分子与人类宿主进行交流。例如，由肠道微生物组产生的分子可以对肝脏产生影响，触发脂质的减少产生，并通过触发肠道中血清素的产生对大脑产生影响。CHAIN生物技术有限公司将开发无害的肠道细菌，以增加天然分子的产生，这些分子通常缺乏患有或有可能患上2型疾病的患者。糖尿病（T2D）和结肠炎。我们的第一个重点将是T2D，它给医疗保健行业带来了巨大的商业和医疗负担，并可能对患者造成破坏性影响，如截肢或视力丧失。该项目的成功可能会导致与微生物组紊乱和炎症背景相关的其他疾病的治疗，如炎症性肠病，亨廷顿病和阿尔茨海默病。"

"The gut microbiome, the collection of bacteria, viruses and fungi inhabiting the human gastrointestinal tract, has a profound impact on the development and maintenance of a healthy immune system. From birth, the microbiome influences how the human immune system responds to resident and invading microbes, which in turn influences our susceptibility to common diseases and long-term health outcomes. Recent advances in microbiome research have highlighted the importance of a healthy gut in prevention of several diseases, ranging from irritable bowel syndrome, to inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, antibiotic associated diarrhoea (including _Clostridium difficile_ associated disease), autism, obesity and type 2 diabetes mellitus. The bacteria present in the gut communicate with the human host by making molecules that not only influence the gut lining but have widespread effects throughout the body. For example, molecules produced by the gut microbiome can have effects on the liver triggering a reduced production of lipids, and the brain by triggering production of serotonin in the gut.In this project, CHAIN Biotechnology Ltd will develop harmless gut bacteria to increase the production of naturally occurring molecules that are often lacking in patients who are suffering from or who are at risk of developing diseases such as type 2 diabetes (T2D) and colitis. Our first focus will be on T2D, which places a huge commercial and medical burden on the healthcare industry and can have devastating effects for sufferers such as amputations or loss of vision. Success in this project may lead to treatments for other conditions that have been associated with a disturbance of the microbiome and an inflammatory background such as inflammatory bowel disease, Huntington's disease and Alzheimer's disease."